FOLH1 and prostate carcinoma: Current evidence and guidelines recommend radiation therapy with androgen deprivation therapy as the preferred treatment for prostate cancer with node-positive disease detected by conventional imaging.4,5 However, it is unknown whether men with positive nodes detectable by PSMA PET but undetectable by conventional imaging benefit preferentially from radiotherapy.